Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Open access
Callaghan, Michael U., Negrier, Claude, Paz-Priel, Ido, Chang, Tiffany, Chebon, Sammy, Lehle, Michaela, Mahlangu, Johnny, Young, Guy, Kruse-Jarres, Rebecca, Mancuso, Maria Elisa, Niggli, Markus, Howard, Monet, Bienz, Nives Selak, Shima, Midori, Jiménez-Yuste, Victor, Schmitt, Christophe, Asikanius, Elina, Levy, Gallia G., Pipe, Steven W., Oldenburg, Johannes · 2021 · Blood

Abstract

Prophylaxis with emicizumab, a subcutaneously administered bispecific humanized monoclonal antibody, promotes effective hemostasis in persons with hemophilia A (PwHAs). The primary efficacy, safety, and pharmacokinetics of emicizumab were reported previously, but long-term data were limited. Here, data from 401 pediatric and adult PwHAs with/without factor VIII (FVIII) inhibitors who were enrolled in the phase 3 HAVEN 1, HAVEN 2, HAVEN 3, and HAVEN 4 studies (NCT02622321, NCT02795767, NCT02847637, NCT03020160) have been pooled to establish a long-term efficacy, safety, and pharmacokinetics profile. Across a median efficacy period of 120.4 weeks (interquartile range, 89.0-164.4) (data cutoff 15 May 2020), the model-based treated annualized bleed rate (ABR) was 1.4 (95% confidence interval [CI], 1.1-1.7). ABRs declined and then stabilized at <1 in an analysis of 24-week treatment intervals; at weeks 121 to 144 (n = 170), the mean treated ABR was 0.7 (95% CI, 0-5.0). During weeks 121 to 144, 82.4% of participants had 0 treated bleeds, 97.6% had ≤3 treated bleeds, and 94.1% reported no treated target joint bleeds. Bleeding into target joints decreased substantially. Emicizumab was well tolerated, and no participant discontinued because of adverse events beyond the 5 previously described. This data cutoff includes the previously reported 3 thrombotic microangiopathies (one in the PwHA with fatal rectal hemorrhage) and 2 thromboembolic events, all associated with activated prothrombin complex concentrate use, as well as a myocardial infarction and a venous device occlusion. With 970.3 patient-years of exposure, emicizumab prophylaxis maintained low bleed rates in PwHAs of all ages with/without FVIII inhibitors and remains well tolerated, with no new safety concerns identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020009217

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 307

Metadata

Authors
Callaghan, M. U., Negrier, C., Paz-Priel, I., Chang, T., Chebon, S., Lehle, M., Mahlangu, J., Young, G., Kruse-Jarres, R., Mancuso, M. E., Niggli, M., Howard, M., Bienz, N. S., Shima, M., Jiménez-Yuste, V., Schmitt, C., Asikanius, E., Levy, G. G., Pipe, S. W., & Oldenburg, J.
Venue
Blood
Published
2021-04-22
Volume
137
Issue
16
Pages
2231-2242
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3115183047
Cited by
307
References
15
FWCI
18.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. https://app.cochat.ai/papers/10.1182/blood.2020009217
The paper
Callaghan, M. U., Negrier, C., Paz-Priel, I., Chang, T., Chebon, S., Lehle, M., Mahlangu, J., Young, G., Kruse-Jarres, R., Mancuso, M. E., Niggli, M., Howard, M., Bienz, N. S., Shima, M., Jiménez-Yuste, V., Schmitt, C., Asikanius, E., Levy, G. G., Pipe, S. W., & Oldenburg, J. (2021). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. https://doi.org/10.1182/blood.2020009217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.